Navidea Biopharma (NAVB) Tops Q4 EPS by 1c, Revenues Miss

March 24, 2021 4:23 PM EDT
Get Alerts NAVB Hot Sheet
Price: $1.74 -8.42%

EPS Growth %: +26.7%

Today's EPS Names:
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $219.25 thousand versus the consensus estimate of $600 thousand.

Michael Rosol, Ph.D., Chief Medical Officer for Navidea, said, “The clinical research team is working diligently to advance the technology in key disease areas, with an emphasis on our RA program. We have completed all patients and all visits in our NAV3-31 Phase 2B trial and we are eagerly anticipating feedback from the FDA on our briefing package and design of the Phase 3 trial. We continue to prepare for initiation of this trial and have also opened up enrollment for the NAV3-32 Phase 2B trial comparing tilmanocept imaging to synovial tissue biopsy samples of RA patients. Concurrent with all of this, we have made exciting progress in our therapeutics pipeline and will continue to advance these towards the clinic.”

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities

Earnings, FDA